From Fed-Batch To Perfusion: Unlocking ROI And Capacity In Monoclonal Antibody Manufacturing

Monoclonal antibodies (mAbs) continue to dominate the biopharmaceutical landscape, with FDA approvals and market growth accelerating year over year. As demand rises—driven by their success in treating cancer, autoimmune, and chronic inflammatory diseases—manufacturers face mounting pressure to deliver therapies faster, more efficiently, and at lower cost. The need for flexible, multiproduct facilities is more urgent than ever, especially as production scales vary widely across indications. While fed-batch remains the industry standard for upstream mAb production, its limitations are becoming more apparent in today’s fast-paced environment. Larger bioreactors, fixed culture durations, and lower volumetric productivity challenge manufacturers aiming to stay competitive.

Access the full white paper to explore the evolving demands of mAb manufacturing and the strategic shifts needed to meet them.